Mobile

An open-label study to evaluate the effectiveness, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset on Crohn's disease versus subject with longer exisiting ...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-005376-29

An open-label study to evaluate the effectiveness, safety and the healing of the mucosa of the bowel of vedolizumab in subject with early onset on Crohn's disease versus subject with longer exisiting Crohn's disease. Een open-label studie om het effect, de veiligheid en de genezing van het darmslijmvlies bij het gebruik van vedolizumab te vergelijken in een vroeg versus een later stadium van de ziekte van Crohn

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this prospective open label study is to assess the ability of vedolizumab to promote clinical, endoscopic and histological remission in patients with active Crohn's disease in an 'early' and a 'late' disease population after 54 weeks of treatment.

Critère d'inclusion

  • Active Crohn's disease,Actieve ziekte van Crohn

Liens